Skip to Content
Merck

NF-Y activates genes of metabolic pathways altered in cancer cells.

Oncotarget (2015-12-10)
Paolo Benatti, Maria Luisa Chiaramonte, Mariangela Lorenzo, John A Hartley, Daniel Hochhauser, Nerina Gnesutta, Roberto Mantovani, Carol Imbriano, Diletta Dolfini
ABSTRACT

The trimeric transcription factor NF-Y binds to the CCAAT box, an element enriched in promoters of genes overexpressed in tumors. Previous studies on the NF-Y regulome identified the general term metabolism as significantly enriched. We dissect here in detail the targeting of metabolic genes by integrating analysis of NF-Y genomic binding and profilings after inactivation of NF-Y subunits in different cell types. NF-Y controls de novo biosynthetic pathways of lipids, teaming up with the master SREBPs regulators. It activates glycolytic genes, but, surprisingly, is neutral or represses mitochondrial respiratory genes. NF-Y targets the SOCG (Serine, One Carbon, Glycine) and Glutamine pathways, as well as genes involved in the biosynthesis of polyamines and purines. Specific cancer-driving nodes are generally under NF-Y control. Altogether, these data delineate a coherent strategy to promote expression of metabolic genes fuelling anaerobic energy production and other anabolic pathways commonly altered in cancer cells.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Vinculin antibody, Mouse monoclonal, clone V284, purified from hybridoma cell culture